This suggests that at the time of an initial colon cancer diagnosis, PAK6 expression might be used to not only identify the optimal individualized treatment, but also to distinguish patients who are more likely to benefit from chemotherapy after surgery. This evidence concerns the gene PAK6 and colonic neoplasm.